Soluble tumour necrosis factor receptor type II and survival in colorectal cancer
View/ Open
Author
Babic, Ana
Shah, Sonali M
Meyerhardt, Jeffrey A
Yuan, Chen
Fuchs, Charles S
Ng, Kimmie
Note: Order does not necessarily reflect citation order of authors.
Published Version
https://doi.org/10.1038/bjc.2016.85Metadata
Show full item recordCitation
Babic, A., S. M. Shah, M. Song, K. Wu, J. A. Meyerhardt, S. Ogino, C. Yuan, et al. 2016. “Soluble tumour necrosis factor receptor type II and survival in colorectal cancer.” British Journal of Cancer 114 (9): 995-1002. doi:10.1038/bjc.2016.85. http://dx.doi.org/10.1038/bjc.2016.85.Abstract
Background: Chronic inflammation may play a role in colorectal cancer (CRC) pathogenesis. The relationship between soluble tumour necrosis factor receptor type II (sTNF-RII) and survival among CRC patients is not well defined. Methods: We prospectively evaluated the association between pre-diagnosis plasma levels of sTNF-RII and mortality in 544 CRC patients from the Nurses' Health Study and Health Professionals Follow-Up Study diagnosed from 1990 to 2010. Primary and secondary end points were overall and CRC-specific mortality, respectively. Cox proportional hazards models were used to calculate multivariate hazard ratios for mortality. Results: Higher sTNF-RII levels were significantly associated with increased overall mortality (multivariate HR=1.48, 95% CI 1.02–2.16, P-trend=0.006), but not with CRC-specific mortality (HR=1.23, 95% CI 0.72–2.08, P-trend=0.34). In subgroup analyses, among regular aspirin users, those with higher sTNF-RII levels had an adjusted HR of 0.52 (95% CI 0.20–1.33) for overall mortality compared with those with lower sTNF-RII levels, whereas among nonregular aspirin users the adjusted HR was 2.26 (95% CI 1.23–4.01, P for interaction=0.53). Conclusions: Among CRC patients, higher sTNF-RII levels are associated with a significant increase in overall mortality, but not CRC-specific mortality. The role of inflammation and anti-inflammatory medications in survival of CRC patients warrants further exploration.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4984918/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:32630718
Collections
- HMS Scholarly Articles [17922]
- SPH Scholarly Articles [6362]
Contact administrator regarding this item (to report mistakes or request changes)